Sandy Robbins

Before joining MMS, Sandy accumulated over 18 years of experience in the CRO industry, holding various Commercial and Finance leadership roles. Her background includes expertise in developing pricing models, supervising proposal and contract workflows, optimizing CRM data structures, and crafting management reports and dashboards. Sandy’s goal is to ensure that MMS has the right processes, systems, and personnel in place to support its ongoing commercial growth and expansion.

Sandy’s educational credentials include an MBA in Finance from the University of Chicago Booth School of Business, along with a bachelor’s degree in chemical engineering from the University of Illinois at Urbana-Champaign. She also holds certifications in Six Sigma and Digital Health, further exemplifying her broad skillset and commitment to professional development.

Suggested For You

perspectives

July 1st, 2025

Why Real-Time Data Access Matters (and How to Make the Most of It)

webinar

July 31st, 2025

Design, Data, and Decisions in Oncology Trials

perspectives

June 24th, 2025

Why Now Is the Time for Specialized, Data-Focused CRO Partners

news

June 19th, 2025

MMS Wins in the 2025 Fierce CRO Awards for Excellence in Client Service and Partnership and Dr. Uma Sharma Named CRO Champion 

perspectives

June 17th, 2025

Solving Data Complexity with Real-Time Insights, Predictive AI, and Smarter Decision-Making with Datacise

regulatory intelligence

June 16th, 2025

Key MedDRA Coding Gaps Highlighted at the ISCTM 2025 Scientific Meeting

perspectives

June 10th, 2025

Applying Artificial Intelligence (AI) and Real-World Evidence to Boost Efficiency in Patient Safety Narratives 

perspectives

June 3rd, 2025

Choosing the Right Strategy: Parallel, Sequential, and Staggered Regulatory Submissions 

news

May 28th, 2025

MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award 

perspectives

May 28th, 2025

A Season of Change: Why the REMS Industry Consortium Matters More Than Ever

perspectives

May 20th, 2025

Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors

perspectives

May 6th, 2025

Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn